Trial of Lamivudine in Inactive HBsAg Carriers with Persistent Hepatitis B Core IgM Antibody
نویسندگان
چکیده
منابع مشابه
Significance of Hepatitis B Core Antibody as the Only Marker of Hepatitis B Virus Infection in High Risk Patients
Background and Objective: Presence of hepatitis B core antibody (anti-HBc) in the absence of hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) is defined, as isolated anti-HBc. little is known about the clinical significance of the isolated anti-HBc in hepatitis B virus (HBV) infections. The aim of this study was to assess the significance of anti-HBc as the onl...
متن کاملOccupational Stress Suppress Production of Anti-HBsAg Antibody in Nurse Staffs Following Hepatitis B Vaccination
Background and Objectives: Vaccination is the major strategy to protect nurses against infection with hepatitis B virus. However, some nurses do not produce sufficient amount of anti-HBsAg antibody required for immunity against infection. Chronic occupational stress has been proposed as a risk factor to humoral immunity. Given that nursing staff is exposed to occupational stress risk, this stud...
متن کاملSerum Galectin-3 Levels in Children with Chronic Hepatitis B Infection and Inactive Hepatitis B Carriers
BACKGROUND Chronic hepatitis B virus (HBV) infection is common worldwide. Follow-up of patients by the use of non-invasive techniques may be valuable in clinical practice. The aim of this study was to investigate serum galectin-3 (GAL-3) levels for monitoring disease status in children with chronic HBV infection. MATERIAL/METHODS Thirty-two patients with chronic hepatitis B (CHB), 30 inactive...
متن کاملClinical trial of lamivudine in children with chronic hepatitis B.
BACKGROUND Lamivudine therapy is effective for chronic hepatitis B infection in adults. We evaluated the efficacy and tolerability of lamivudine as a treatment for chronic infection with hepatitis B virus (HBV) in children. METHODS Children with chronic hepatitis B were randomly assigned in a 2:1 ratio to receive either oral lamivudine (3 mg per kilogram of body weight; maximum, 100 mg) or pl...
متن کاملPriming Hepatitis B Surface (HBsAg)- and Core Antigen (HBcAg)-Specific Immune Responses by Chimeric, HBcAg with a HBsAg ‘a’ Determinant
We developed an immunogen to stimulate multivalent immunity against hepatitis B surface antigen (HBsAg) and hepatitis B core antigens (HBcAg). Immune responses specific for both HBsAg and HBcAg play an important role in controlling the infection. HBsAg-specific antibodies mediate elimination of virions at an early stage of infection and prevent the spread of virus. The immunogen was constructed...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Infectious Diseases
سال: 2008
ISSN: 1201-9712
DOI: 10.1016/j.ijid.2008.05.1093